[ad_1]
Principal Financial Group Inc. increased its holdings in Intersect ENT Inc. (NASDAQ: XENT) shares by 10.1% during the first quarter, according to the investor Institutional held 16,564 shares of the medical equipment supplier after the acquisition of 1,524 additional shares during the quarter, while Principal Financial Group Inc. held approximately 0.05% of Intersect's outstanding shares. $ 651,000 at the end of the fiscal year. A number of other institutional investors and hedge funds have also changed their holdings in equities, while Teachers Retirement System of the State of Kentucky has increased its position in Intersect ENT by 4.1% over the past year. fourth trimester. The Teachers Retirement System of the State of Kentucky now owns 42,584 shares of the medical equipment provider valued at $ 1,380,000 after acquiring 1,696 last-quarter shares. Northern Trust Corp increased its position in Intersect ENT by 0.6% in the first quarter. Northern Trust Corp. now holds 354,976 medical equipment supplier shares valued at $ 13,952,000 after acquiring 2,036 additional shares in the last quarter. Prudential Financial Inc. increased its position in Intersect ENT by 20.3% in the first quarter. Prudential Financial Inc. now owns 13,761 shares in the medical equipment supplier valued at $ 541,000 after acquiring 2,320 additional shares in the last quarter. The Swiss National Bank raised its position in Intersect ENT by 7.0% in the first quarter. The Swiss National Bank now holds 45,800 shares in the medical equipment supplier valued at USD 1,800,000 after acquiring 3,000 additional shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in Intersect ENT during the first quarter, valued at approximately $ 132,000. 88.54% of the shares are currently held by hedge funds and other institutional investors.
Several brokerages recently weighed on XENT. BidaskClub has raised shares of the Intersect ENT from a "hold" rating to a "buy" note in a research report on Thursday, June 28. ValuEngine has upgraded Intersect ENT from a "buy" rating to a "strong-buy" rating in a report on Wednesday, May 2nd. Northland Securities reiterated a "hold" rating and set a target price of $ 32.00 on Intersect shares in a report on Wednesday, May 2. BTIG Research reiterated a "hold" rating on Intersect shares in a report on Wednesday, May 2nd. Finally, JPMorgan Chase & Co. reiterated an "overweight" rating and set a price target of $ 48.00 on Intersect shares in a report on Wednesday, May 2nd. Two equity research badysts gave a rating to the stock and ten attributed a purchase grade to the company. The stock currently has an average rating of "Buy" and an average price target of $ 38.50.
Shares of the Intersect ENT opened at $ 33.70 on Friday, according to MarketBeat Ratings reports. Intersect ENT Inc. has a minimum of 12 months of $ 26.90 and a 12-month high of $ 42.95. The company has a market capitalization of $ 1.07 billion, a price-earnings ratio of -60.18 and a beta of 0.77.
Intersect ENT (NASDAQ: XENT) last announced its quarterly results on Tuesday, May 1st. The medical equipment provider reported earnings per share of $ 0.21 for the quarter, compared with $ 0.02 for the consensus estimate of $ 0.23. Intersect ENT had a negative return on equity of 13.67% and a negative net margin of 15.73%. The company achieved a turnover of $ 24.70 million for the quarter, compared to the consensus estimate of $ 23.66 million. During the same quarter last year, the company posted earnings per share of $ 0.23. The company's business figure for the quarter is up 20.5% over the same quarter of last year. Equity research badysts predict that "Intersect ENT Inc. will post earnings per share of -0.63 for the current year.
In addition, the chief operating officer, Richard E. Kaufman, sold 7,000 shares of the company in a transaction on Tuesday, July 10. The shares were sold at an average price of $ 35.02, for a total value of $ 245,140.00. As a result of the sale, the Chief Operating Officer now owns 94,512 shares of the company, valued at $ 3,309,810.24. The sale was disclosed in a SEC deposit, which is available at this hyperlink. In addition, Jeryl L. Hilleman, Chief Financial Officer, sold 12,833 shares of the fund in a transaction on Thursday, May 3rd. The stock was sold at an average price of $ 39.94, for a total transaction of $ 512,550.02. Following the closing of the sale, the Chief Financial Officer now holds 36,265 shares of the Company, valued at approximately $ 1,448,424.10. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 67,666 shares valued at $ 2,622,476. 5.90% of the shares are currently held by insiders.
About Intersect ENT
Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients suffering from diseases of the ears, nose and throat in the United States. It offers implants releasing PROPEL and PROPEL mini-drugs for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, an implant releasing steroids to the frontal and maxillary sinuses, or openings, of the dependent sinuses.
Receive News & Ratings for Intersect ENT Daily – Enter your email address below to receive a concise daily summary of the latest news and badyst ratings for Intersect ENT and related companies with MarketBeat. The FREE daily electronic newsletter of com.
Source link
